{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:48:47Z","timestamp":1782193727921,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"the Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["JP21K10478"],"award-info":[{"award-number":["JP21K10478"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"the Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["JP25K02854"],"award-info":[{"award-number":["JP25K02854"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004088","name":"Kowa Life Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10157-026-02865-2","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T22:58:59Z","timestamp":1775861939000},"page":"1010-1020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of individual sodium-glucose cotransporter-2 inhibitors on all-cause mortality in patients with diabetic kidney disease"],"prefix":"10.1007","volume":"30","author":[{"given":"Hiroki","family":"Nobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-1239","authenticated-orcid":false,"given":"Michihiro","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Iwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Yagihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Metoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"2865_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","volume":"25","author":"DN Koye","year":"2018","unstructured":"Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25:121\u201332.","journal-title":"Adv Chronic Kidney Dis"},{"key":"2865_CR2","volume":"374","author":"B Zinman","year":"2016","unstructured":"Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med. 2016;374:1094.","journal-title":"N Engl J Med"},{"key":"2865_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"2865_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"2865_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2865_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in Type 2 Diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2865_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"2865_CR8","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/clc.23508","volume":"43","author":"ME Johansen","year":"2020","unstructured":"Johansen ME, Argyropoulos C. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now. Clin Cardiol. 2020;43:1376\u201387.","journal-title":"Clin Cardiol"},{"key":"2865_CR9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21:1237\u201350.","journal-title":"Diabetes Obes Metab"},{"key":"2865_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031805","volume":"13","author":"R Kani","year":"2024","unstructured":"Kani R, Watanabe A, Miyamoto Y, Ejiri K, Iwagami M, Takagi H, et al. Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2024;13:e031805.","journal-title":"J Am Heart Assoc"},{"key":"2865_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915\u201320.","journal-title":"Am J Epidemiol"},{"key":"2865_CR12","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hernan","year":"2022","unstructured":"Hernan MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328:2446\u20137.","journal-title":"JAMA"},{"key":"2865_CR13","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1038\/s41440-024-01875-5","volume":"47","author":"M Satoh","year":"2024","unstructured":"Satoh M, Nakayama S, Toyama M, Hashimoto H, Murakami T, Metoki H. Usefulness and caveats of real-world data for research on hypertension and its association with cardiovascular or renal disease in Japan. Hypertens Res. 2024;47:3099\u2013113.","journal-title":"Hypertens Res"},{"key":"2865_CR14","first-page":"190","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5:190\u20138.","journal-title":"JMA J"},{"key":"2865_CR15","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1097\/HJH.0000000000003186","volume":"40","author":"M Satoh","year":"2022","unstructured":"Satoh M, Hirose T, Satoh H, Nakayama S, Obara T, Murakami T, et al. Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients. J Hypertens. 2022;40:1564\u201376.","journal-title":"J Hypertens"},{"key":"2865_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41440-023-01452-2","volume":"47","author":"M Satoh","year":"2024","unstructured":"Satoh M, Muroya T, Murakami T, Obara T, Asayama K, Ohkubo T, et al. The impact of clinical inertia on uncontrolled blood pressure in treated hypertension: real-world, longitudinal data from Japan. Hypertens Res. 2024;47:598\u2013607.","journal-title":"Hypertens Res"},{"key":"2865_CR17","unstructured":"The Ministry of Health LaW. Standard health checkup and health guidance programs (2018). https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000194155.html. Accessed 12\/Jul\/2024."},{"key":"2865_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","volume":"56","author":"M Horio","year":"2010","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32\u20138.","journal-title":"Am J Kidney Dis"},{"key":"2865_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171106","volume":"12","author":"JI Park","year":"2017","unstructured":"Park JI, Baek H, Kim BR, Jung HH. Comparison of urine dipstick and albumin:creatinine ratio for chronic kidney disease screening: a population-based study. PLoS ONE. 2017;12:e0171106.","journal-title":"PLoS ONE"},{"key":"2865_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jacl.2024.12.006","volume":"19","author":"M Satoh","year":"2025","unstructured":"Satoh M, Nakayama S, Hashimoto H, Toyama M, Iwabe Y, Yagihashi T, et al. Differential coronary heart disease risk among antihypertensive and lipid-lowering medication users versus non-users: A real-world data analysis. J Clin Lipidol. 2025;19:294\u2013302.","journal-title":"J Clin Lipidol"},{"key":"2865_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1253\/circj.CJ-22-0566","volume":"87","author":"K Kanaoka","year":"2023","unstructured":"Kanaoka K, Iwanaga Y, Okada K, Terasaki S, Nishioka Y, Nakai M, et al. Validity of diagnostic algorithms for cardiovascular diseases in Japanese health insurance claims. Circ J. 2023;87:536\u201342.","journal-title":"Circ J"},{"key":"2865_CR22","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107.","journal-title":"Stat Med"},{"key":"2865_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323\u201337.","journal-title":"J Clin Epidemiol"},{"key":"2865_CR24","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"HVS Quan","year":"2005","unstructured":"Quan HVS, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"2865_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066116","volume":"8","author":"N Ooba","year":"2013","unstructured":"Ooba N, Setoguchi S, Ando T, Sato T, Yamaguchi T, Mochizuki M, et al. Claims-based definition of death in Japanese claims database: validity and implications. PLoS ONE. 2013;8:e66116.","journal-title":"PLoS ONE"},{"key":"2865_CR26","first-page":"1","volume":"25","author":"T Kimura","year":"2020","unstructured":"Kimura T, Sugitani T, Nishimura T, Ito M. Validation and recalibration of Charlson and Elixhauser comorbidity indices to predict in-hospital mortality in hospitalized patients in a Japanese hospital-based administrative database. Jpn J Pharmacoepidemiol. 2020;25:1\u201314.","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"2865_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E Von Elm","year":"2008","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"2865_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","volume":"21","author":"Y Suzuki","year":"2022","unstructured":"Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, et al. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovasc Diabetol. 2022;21:67.","journal-title":"Cardiovasc Diabetol"},{"key":"2865_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamainternmed.2024.7357","volume":"185","author":"H Shin","year":"2025","unstructured":"Shin H, Paik JM, Everett BM, DiCesare E, Alix C, Glynn RJ, et al. Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors. JAMA Intern Med. 2025;185:302\u201313.","journal-title":"JAMA Intern Med"},{"key":"2865_CR30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102:990\u20139.","journal-title":"Kidney Int"},{"key":"2865_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1055\/s-0043-104779","volume":"67","author":"N Kasahara-Ito","year":"2017","unstructured":"Kasahara-Ito N, Fukase H, Ogama Y, Saito T, Ohba Y, Shimada S, et al. Pharmacokinetics and pharmacodynamics of Tofogliflozin (a selective SGLT2 inhibitor) in healthy male subjects. Drug Res. 2017;67:349\u201357.","journal-title":"Drug Res"},{"key":"2865_CR32","volume":"16","author":"S Inoue","year":"2024","unstructured":"Inoue S, Yasuda H, Yoshida K, Mori K, Ogawa K, Yokotsuka Y, et al. Effects of switching from another sodium-glucose cotransporter 2 inhibitor to Tofogliflozin on nocturia in patients with type 2 diabetes. Cureus. 2024;16:e59411.","journal-title":"Cureus"},{"key":"2865_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83\u201390.","journal-title":"Diabetes Obes Metab"},{"key":"2865_CR34","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.34067\/KID.0002772021","volume":"2","author":"EM Wright","year":"2021","unstructured":"Wright EM. SGLT2 inhibitors: Physiology and pharmacology. Kidney360. 2021;2:2027\u201337.","journal-title":"Kidney360"},{"key":"2865_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12933-024-02478-7","volume":"23","author":"Y Mori","year":"2024","unstructured":"Mori Y, Komura T, Adomi M, Yagi R, Fukuma S, Kondo N, et al. Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study. Cardiovasc Diabetol. 2024;23:372.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02865-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02865-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02865-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:40:06Z","timestamp":1782193206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02865-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2865"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02865-2","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michihiro S received academic support from the Kowa Life Science Foundation, which is funded by Kowa Co., Ltd., and Bayer Yakuhin Co., Ltd., and has received honoraria (lecture fees) from AstraZeneca K.K. and Fuji Yakuhin Co., Ltd. Division of Public Health, Hygiene and Epidemiology (Tohoku Medical and Pharmaceutical University) received research grants from Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Baxter International Inc., and Bayer Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Research Ethics Committee for Life Science and Medical Research of Tohoku Medical and Pharmaceutical University (approval ID: 2024\u20132-015). The requirement for informed consent was waived because all data were fully de-identified before analysis. This study was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}